Tuesday, December 19, 2017 7:46:34 PM
CLSN...Nov 21,17 Celsion Corporation (NASDAQ: CLSN) shares...Oppenheimer analyst Hartaj Singh initiated coverage on the company with an Outperform rating and $9 price target.
...chemotherapy, DNA-mediated immunotherapy, and RNA based therapy products for the treatment of cancer. The company's lead product includes ThermoDox, a liposomal encapsulation of doxorubicin that is in Phase III clinical trials for primary liver cancer; and under Phase II clinical trials for recurrent chest wall breast cancer. It is also developing GEN-1, a DNA-based immunotherapeutic product for the localized treatment of ovarian and brain cancers. Celsion Corporation was founded in 1982 and is headquartered in Lawrenceville, New Jersey.
CLSN (T/$9) chemotherapy, DNA-mediated immunotherapy, and RNA based therapy products for the treatment of cancer.
...chemotherapy, DNA-mediated immunotherapy, and RNA based therapy products for the treatment of cancer. The company's lead product includes ThermoDox, a liposomal encapsulation of doxorubicin that is in Phase III clinical trials for primary liver cancer; and under Phase II clinical trials for recurrent chest wall breast cancer. It is also developing GEN-1, a DNA-based immunotherapeutic product for the localized treatment of ovarian and brain cancers. Celsion Corporation was founded in 1982 and is headquartered in Lawrenceville, New Jersey.
CLSN (T/$9) chemotherapy, DNA-mediated immunotherapy, and RNA based therapy products for the treatment of cancer.
Join the InvestorsHub Community
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
